rheumatology

RA drug approved for use in coronavirus cytokine storm

China has approved the use of tocilizumab (Actemra) for people with coronavirus on the basis of its effects against a cytokine storm. The anti-inflammatory bDMARD is already approved in the US for RA and the treatment of severe or life-threatening cytokine release syndrome (CRS) such as in patients receiving CAR T-cell therapy, and now clinicians ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic